ReShape Lifesciences Inc. held a special meeting of stockholders on July 24, 2025. Stockholders approved the issuance of shares of Common Stock in connection with the proposed merger with Vyome Therapeutics, Inc. Additionally, the authorization of the Board of Directors to amend the Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock was approved. The meeting was adjourned to further solicit votes on the proposal to approve the sale of substantially all of the company's assets to Ninjour Health International Limited and on the proposal to approve and adopt proposed amendments to the company's Restated Certificate of Incorporation in connection with the proposed merger. The meeting will resume on August 7, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-070826), on July 25, 2025, and is solely responsible for the information contained therein.
Comments